Table 1.
Baseline Features of Inverse Probability Weighted Older Men and Women With Myocardial Infarction
| Variable | Men | Women | P value | |SMD| |
|---|---|---|---|---|
| n=16 083 | n=15 495 | |||
| Age, y (SD) | 79.3 (6.1) | 79.3 (6.1) | 0.858 | 0.002 |
| Comorbidities | ||||
| Alcohol abuse | 1.2% | 1.1% | 0.898 | 0.001 |
| Anemia | 5.0% | 4.9% | 0.849 | 0.002 |
| Atrial fibrillation | 22.1% | 22.4% | 0.619 | 0.006 |
| Cerebrovascular disease | 14.9% | 14.8% | 0.875 | 0.002 |
| Chronic pulmonary disease | 15.5% | 15.7% | 0.655 | 0.005 |
| Coagulopathy | 0.4% | 0.4% | 0.642 | 0.005 |
| Dementia | 8.5% | 8.3% | 0.648 | 0.005 |
| Depression | 10.7% | 10.7% | 0.942 | 0.001 |
| Diabetes | 27.5% | 27.5% | 0.883 | 0.002 |
| Insulin dependent | 9.0% | 9.2% | 0.707 | 0.004 |
| Noninsulin dependent | 18.4% | 18.4% | 0.913 | 0.001 |
| Heart failure | 30.6% | 30.7% | 0.919 | 0.001 |
| Hypertension | 57.6% | 57.8% | 0.715 | 0.004 |
| Hypothyroidism | 5.9% | 5.9% | 0.977 | 0.0003 |
| Liver disease | 0.7% | 0.8% | 0.667 | 0.005 |
| Malignancy | 15.9% | 16.2% | 0.429 | 0.009 |
| Metastatic tumor | 0.3% | 0.3% | 0.887 | 0.002 |
| Paralysis | 0.4% | 0.4% | 0.975 | 0.0003 |
| Peripheral vascular disease | 9.3% | 9.3% | 0.928 | 0.001 |
| Prior CABG | 4.4% | 4.4% | 0.841 | 0.002 |
| Prior MI | 22.9% | 23.0% | 0.893 | 0.002 |
| Psychotic disorder | 2.9% | 2.9% | 0.815 | 0.003 |
| Rheumatic disease | 7.3% | 7.3% | 0.865 | 0.002 |
| Renal failure | 4.2% | 4.1% | 0.624 | 0.006 |
| Valvular disease | 7.4% | 7.4% | 0.906 | 0.001 |
| Revascularization | 42.7% | 42.3% | 0.534 | 0.001 |
| Percutaneous coronary intervention | 36.4% | 36.1% | 0.627 | 0.005 |
| CABG | 6.8% | 6.8% | 0.754 | 0.004 |
| ST‐segment–elevation MI | 29.1% | 29.2% | 0.948 | 0.001 |
| Anterior* | 53.2% | 52.9% | 0.819 | 0.005 |
| Post‐MI medication | ||||
| ADP inhibitor | 53.8% | 53.9% | 0.935 | 0.001 |
| Prasugrel or ticagrelor † | 6.8% | 6.5% | 0.530 | 0.002 |
| Anticoagulant | 17.3% | 17.4% | 0.906 | 0.001 |
| Direct oral anticoagulant ‡ | 0.9% | 0.6% | 0.136 | 0.039 |
| Angiotensin‐converting‐enzyme inhibitor or angiotensin receptor blocker | 63.2% | 63.3% | 0.953 | 0.001 |
| Aldosterone antagonist | 4.5% | 4.4% | 0.770 | 0.003 |
| Antiarrhythmic | 1.3% | 1.4% | 0.640 | 0.005 |
| Beta blocker | 81.9% | 81.9% | 0.874 | 0.002 |
| Ezetimibe | 1.5% | 1.5% | 0.943 | 0.001 |
| Statin | 73.2% | 73.3% | 0.930 | 0.001 |
| High‐dose statin § | 10.6% | 10.6% | 0.976 | 0.0004 |
| Treating hospital (n=20) | 0.234 | 0.003 | ||
| Admission year | 0.816 | 0.003 | ||
ADP indicates adenosine diphosphate; CABG, coronary artery bypass grafting surgery; MI, myocardial infarction; and SMD, standardized mean difference.
*
Of patients with ST‐segment–elevation MI.
†
Of ADP inhibitor users.
‡
Of anticoagulant users.
§
Of statin users.